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Introduction
The JAK2 V617F mutation is found in about 50-60% of
cases of essential thrombocythemia (ET) while 5-10% of
JAK2 V617F-negative ET patients carry a W515K/L gain-of-
function mutation in exon 10 of MPL, the thrombopoietin
receptor gene.1-5 Recently, indels in CALR have been described
in about 70% of cases of JAK2/MPL wild-type (double-nega-
tive) ET and primary myelofibrosis (PMF), in a mutually
exclusive pattern with JAK2 and MPLmutations. CALRmuta-
tions were not found in other myeloid malignancies, with the
exception of the myelodysplastic syndrome, refractory ane-
mia with ring sideroblasts and thrombocytosis.6,7 CALR indels
are variable but all cause a +1 frameshift leading to a novel C-
terminal lacking the KDEL endoplasmic reticulum targeting
sequence. CALR mutations have also been identified in famil-
ial cases of ET (11%) and PMF (30%).8
Several recent studies have analyzed the clinical and hema-
tologic features of ET or PMF patients according to their
mutational genotype.6,7,9-13 These studies have shown that
CALR-mutated cases are associated with younger age, higher
platelet counts, lower erythrocyte counts, lower leukocyte
counts, and lower hemoglobin levels compared with JAK2-
mutated cases. In addition, in most of these studies CALR
mutations were linked to male gender. However, the impact
of the mutations on overall survival seems to differ between
cases of ET and PMF.
We retrospectively analyzed a Belgian cohort of 103 JAK2
V617F-negative ET patients for the presence of MPL and
CALR mutations. In addition, we compared the clinical and
hematologic phenotypes of CALR mutant cases with those of
a control cohort of 57 JAK2 V617F-positive ET patients, as
well as with a group of triple-negative ( JAK2 V617F-negative,
MPLW515K/L-negative, and CALRmutant-negative) patients
with ET. 
Methods
Patients and clinical information
This study was approved by the local ethical committee of UZ
Leuven (study S53745). All patients selected for this study were seen
at hematology units of academic or large regional Belgian hospitals
between 1980 and 2013. Inclusion criteria were a diagnosis of ET
[based on World Health Organization (WHO) 2008 criteria14], and the
availability of stored bone marrow or peripheral blood for molecular
analysis. Given that an initial bone marrow biopsy was not available
for all cases, the presence of any two minor criteria for PMF (WHO
2008) was an exclusion criterion for this study, if no bone marrow
biopsy was available, thus eliminating all cases with potential PMF.
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The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) muta-
tions are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essen-
tial thrombocythemia. CALR mutations account for approximately 30% of cases of essential thrombocythemia. In
a retrospective study, we examined the frequency of MPL and CALR mutations in JAK2 V617F-negative cases of
essential thrombocythemia (n=103). In addition, we compared the clinical phenotype and outcome of CALR
mutant cases of essential thrombocythemia with a cohort of JAK2 V617F-positive essential thrombocythemia
(n=57). CALR-positive cases represented 63.7% of double-negative cases of essential thrombocythemia, and most
carried CALR type 1 or type 2 indels. However, we also identified one patient who was positive for both the JAK2
V617F and the CALR mutations. This study revealed that CALR mutant essential thrombocythemia is associated
with younger age, higher platelet counts, lower erythrocyte counts, leukocyte counts, hemoglobin, and hemat-
ocrit, and increased risk of progression to myelofibrosis in comparison with JAK2 V617F-positive essential throm-
bocythemia. Analysis of the CALR mutant group according to indel type showed that CALR type 1 deletion is
strongly associated with male gender. CALR mutant patients had a better overall survival than JAK2 V617F-posi-
tive patients, in particular patients of age 60 years or younger. In conclusion, this study in a Belgian cohort of
patients supports and extends the growing body of evidence that CALR mutant cases of essential thrombo-
cythemia are phenotypically distinct from JAK2 V617F-positive cases, with regards to clinical and hematologic
presentation as well as overall survival. 
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ABSTRACT
First, a cohort of 103 JAK2 V617F-negative ET cases diagnosed
between 1980 and 2013 at several Belgian hospitals was collected
and analyzed for CALR and MPL mutations. We also collected a
control cohort of 57 JAK2 V617F-positive ET patients diagnosed
between 1987 and 2009 in the University Hospitals Leuven. The
median follow-up of the whole cohort of 160 patients was 8 years
(range, 1-34 years). Hematologic parameters (platelet counts, ery-
throcyte counts, leukocyte counts, hemoglobin, and hematocrit) at
diagnosis were retrieved as was information on cardiovascular
events and complications (arterial thrombosis, and venous events).
During follow-up, progression to myelofibrosis, progression to
acute myeloid leukemia, need for cytoreductive treatment, and
presence of splenomegaly were recorded. 
Sequencing
Genomic DNA was extracted from stored bone marrow or
blood samples, and analyzed for the JAK2 V617F mutation by
allele-specific polymerase chain reaction testing.1 The mutational
load of JAK2 V617F was determined with the Ipsogen JAK2
MutaQuant Kit (Qiagen, the Netherlands). JAK2 V617F-negative
patients were sequenced for MPL W515K/L mutations. For the
detection of MPL exon 10 or CALR exon 9 mutations, we applied
polymerase chain reaction amplification and Sanger sequencing,
using previously described primers.6 JAK2 V617F-positive and
double-negative ET patients were sequenced for CALR indels.
Sequencing was done on an ABI PRISM® 3100 Genetic Analyzer
and the sequencing traces obtained were analyzed on CLC Main
Workbench 6 (CLC bio, Denmark). Indels in CALRwere labeled in
accordance with the study by Klampfl et al.6
Statistics
The non-parametric Mann-Whitney test was used for numerical
comparisons while a chi-square test or Fisher exact test was used
for nominal comparisons. The analyses were two-tailed, and P val-
ues <0.05 were considered statistically significant. Overall sur-
vival, leukemia-free survival, and myelofibrosis-free survival were
estimated by Kaplan-Meier analysis and compared using the log-
rank test. Statistical analyses were performed with SPSS software
(version 20).
Results and discussion
First, the JAK2 V617F-negative group of patients (n=103)
diagnosed since 1980 was sequenced for MPL W515K/L
mutations and CALR indels. Sequencing revealed 58 CALR
mutations, 12 MPL W515K/L mutations and no MPL or
CALR mutations in 33 patients (Figure 1). Therefore,
63.7% of JAK2 V617F- and MPL W515K/L-negative
patients were carrying an indel in CALR, which is in line
with previously reported percentages indicating that the
percentage of CALR mutations in this group of patients is
≥50% making CALR the second most recurrently mutated
gene in ET.6,7,9,12 For the comparison of the hematologic and
clinical phenotypes, we selected 57 JAK2 V617F-positive
patients from our internal database of patients diagnosed
since 1987. In contrast with the first published results stat-
ing that JAK2 V617F and CALR mutations are mutually
exclusive,6,7 we identified one JAK2 V617F ET patient with
a type 2 CALR indel who was excluded from further sta-
tistical analysis. This is, to the best of our knowledge, the
fourth ET patient to be reported with both a CALR muta-
tion and a JAK2 V617F mutation. This combination has so
far been reported in several cases of myeloproliferative
neoplasms.11,15-18
Type 1 (c.1092_1143del) and type 2
(c.1154_1155insTTGTC) indels occurred in 35 cases
(60.3%) and 18 cases (31%), respectively. The remaining
indels included five other types of which three were
novel; they were labeled type 41, 42, and 43 in accordance
with Klampfl et al. (Online Supplementary Table S1).
Although novel, these types also lead to typical loss of the
acidic bases and the gain of a novel basic C-terminal, as
with the previously described types.6 Similar frequencies
of type 1 deletion and type 2 insertion in ET have been
reported in several other studies. In the first study by
Klampfl et al. in a cohort of patients with myeloprolifera-
tive neoplasms, 53% and 31.7% carried type 1 or type 2,
respectively.6 In later studies, the incidences of type 1 and
type 2 in the cohorts studied by Tefferi et al., Rumi et al.
and Andrikovics et al. were 48% and 35%, 46% and 38%,
and 50% and 32%, respectively. 
The mean age of patients with CALR mutations was
51.6±17 years (range, 23 and 84), whereas the mean age of
triple-negative patients and JAK2 V617F-positive patients
was 46.6±16.8 years (range, 17-78) and 65±14 years
(range, 36-94), respectively. CALR mutant patients were
younger than JAK2 V617F-positive ones (P<0.001), consis-
tent with previous studies on JAK2 V617F-positive versus
JAK2 V617F-negative myeloproliferative neoplasms.19,20
Also in agreement with previously published data, the
CALR mutation-positive group had more males (56.8 %)
compared to the JAK2 V617F-positive group (39.2%).9,12,13
Patients with a CALR mutation also had higher platelet
counts (mean ± SD: 989.8±371.3x109/L versus 863.4±288.4
x109/L; P=0.03), lower erythrocyte counts (4.4±0.9x1012/L
versus 4.9±0.6x1012/L; P<0.001), lower hemoglobin con-
centration (13.3±1.8 g/dL versus 14.4±1.6 g/dL; P=0.002),
lower hematocrit (40.2±6.1% versus 43.9±4.7%; P<0.001)
and lower leukocyte counts (8.9±2.6x109/L versus 11.6±5.9
x109/L; P=0.001) (Table 1). Several patients progressed to
myelofibrosis or acute myeloid leukemia during the
course of the disease. The percentage of ET patients who
progressed to post-ET myelofibrosis was higher in the
CALR-positive group than in the triple-negative or JAK2
V617F-positive groups (18%, 0%, and 4%, respectively;
P=0.01 and P=0.05, respectively). Overall these compar-
isons indicate that CALR mutation-positive patients
appear to have a higher risk of evolution to myelofibrosis
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Figure 1. Distribution of JAK2 V617F-negative ET patients (n=103)
according to their mutational status.
MPL W515K/L
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Triple negative 32%
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34%
12%
5%
CALR other types
CALR type 2
compared to the JAK2 V617F-positive patients. However,
the median follow-up of the CALR mutation-positive
group (12 years) was longer than that of the JAK2 V617F-
positive group (7 years). The natural history of early/prefi-
brotic PMF is known to be different from that of true ET,
in particular due to higher rates of evolution to overt
myelofibrosis and blast transformation.21 The possibility
of early/prefibrotic PMF at diagnosis was specifically ruled
out in those evolving to myelofibrosis, based on review of
the initial bone marrow biopsy and histopathological cri-
teria for PMF.14 The bone marrow biopsies showed a pro-
liferation mainly of the megakaryocytic lineage with
increased numbers of enlarged, mature megakaryocytes,
rather than bizarre highly atypical megakaryocytes. There
was no significant increase or left-shift of neutrophil gran-
ulopoiesis or erythropoiesis. Previous studies by Nangalia
et al. and Andrikovics et al. also found higher risks of pro-
gression among CALR mutation-positive versus JAK2
V617F-positive ET (15% versus 6%, P=0.034 and 19% ver-
sus 2%; P=0.03).7,22 Other studies found comparable pro-
gression rates to myelofibrosis in CALR mutation-positive
and JAK2 V617F-positive ET.12,13,23
Eighty-six percent of the patients in our study group
started on cytoreductive therapy, most commonly
hydroxyurea, upon diagnosis. The triple-negative group
contained significantly fewer treated patients compared to
CALRmutation-positive and JAK2 V617F-positive patients
(P=0.04, not shown). 
ET is associated with cardiovascular complications
including stroke, acute coronary syndrome, transient
ischemic attack, pulmonary embolism, abdominal throm-
bosis, deep-vein thrombosis, and peripheral arterial
thrombosis. We assessed whether the mutational status
was associated with differences in the incidence of cardio-
vascular complications at diagnosis and arterial thrombo-
sis or venous events. In our cohort of patients the risks of
developing any of these complications did not differ sig-
nificantly between the different molecular subtypes.
We also compared the clinical and hematologic data of
the CALR type 1 and type 2 subgroups and compared
them to those of the JAK2 V617F-positive group (Online
Supplementary Table S2). Remarkably, the male predilec-
tion was confined to the group with CALR type 1 muta-
tion, and this group also had a tendency to the highest
platelet counts and was associated with younger age com-
pared to the JAK2 V617F-positive group. Tefferi et al. also
reported that CALR type 1 is associated with male gender.
However, they also reported that type 2 is associated with
younger age and higher platelet counts,24 which was not
confirmed in our study or by another study published by
Andrikovics et al.22
We divided our JAK2 V617F-positive group into a group
with low mutational load (≤10%; n=11) and another with
high mutational load (>10%; n=46), as determined by
quantitative polymerase chain reaction. However, no sig-
nificant differences between the two groups were
revealed (Online Supplementary Table S3). Given the low
number of patients with a low load of JAK2, this compar-
ison needs to be conducted again in larger groups.
The mean follow-up of the CALRmutation-positive, the
JAK2 V617F-positive and the triple-negative groups was
14, 7, and 7 years, respectively. The median overall sur-
vivals, as evaluated by Kaplan-Meier analysis, were 30
years (95% confidence interval, 25.4 to 34.5), 21 years
(95% confidence interval, not reached), and not reached,
respectively (P=0.015) (Figure 2A). Myelofibrosis-free sur-
vival (Figure 2B) and leukemia-free survival (Figure 2C)
were not significantly different between the CALR muta-
tion-positive group and the JAK2 V617F-positive group
(P=0.65 and P=0.09, respectively). In our study, none of
the triple-negative patients progressed to develop myelofi-
brosis or acute myeloid leukemia.
In the first paper by Klampfl et al., the CALR mutant
group had a better overall survival compared to JAK2
ET with CALR or JAK2 mutations
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Table 1. Hematologic and clinical features of CALR-positive versus JAK2 V617F-positive and triple-negative patients.
CALR-positive JAK2-positive Triple-negative CALR-positive CALR-positive
n=58 n=56 n=33 vs. vs.
JAK2-positive triple-negative
P value P value
Age at diagnosis (mean ± SD, range) 51.6 ± 17 65 ± 14.2 46.6 ± 16.8 <0.001 0.19
Gender (male) 33/58 (56.8%) 22/56 (39.2%) 20/33 0.059 0.67
Platelets  (109/L, mean ± SD) 989.8 ± 371.3 863.4 ± 288.4 939.3 ± 509.6 0.03 0.07
Leukocytes  (109/L, mean ± SD) 8.9 ± 2.6 11.6 ± 5.9 11.1 ± 6.3 0.001 0.1
Erythrocytes (1012/L, mean ± SD) 4.4 ± 0.9 4.9 ± 0.6 4.6 ± 1.2 <0.001 0.09
Hemoglobin (g/dL, mean ± SD) 13.3 ± 1.8 14.4 ± 1.6 13.9 ± 2.1 0.002 0.1
Hematocrit  (percentage, mean ± SD) 40.2 ± 6.1 43.9 ± 4.7 41.7 ± 6 <0.001 0.14
Cytoreductive treatment 51/56 (91%) 49/56 (88%) 24/32 (75%) 0.76 0.06
Splenomegaly 3/50 (6%) 3/46 (7%) 0/32 1 0.27
Cardiovascular complications at diagnosis 9/55 (16%) 8/55 (15%) 2/32 (6%) 0.79 0.3
Arterial thrombosis 11/55 (20%) 9/54 (17%) 4/31 (13%) 0.65 0.55
Venous event 2/49 (4%) 7/54 (13%) 1/31 (3%) 0.16 1
Death 7/51 (14%) 11/48 (23%) 5/31 (16%) 0.24 0.76
Progression to myelofibrosis 9/51 (18%) 2/50 (4%) 0/31 0.05 0.01
Progression to acute myeloid leukemia 4/49 (8%) 3/50 (6%) 0/26 0.71 0.29
Statistically significant values (P<0.05) are shown in bold.
V617F-positive cases or MPL mutant cases in 311 ET cases
and 203 PMF cases.6 However, subsequent studies by
Tefferi et al., Andrikovics et al., and Rumi et al. showed bet-
ter overall survival for CALR mutant cases than for JAK2
V617F-positive cases in PMF,11,22,25 but not in ET.8,11,13,22
Tefferi et al. addressed this divergence by studying survival
in 299 ET cases with long follow-up, but did not find a sur-
vival advantage for CALR-mutated cases even after adjust-
ing for age (≤ or > 65 years).12 Since JAK2 V617F-positive
patients are generally older at diagnosis than CALR muta-
tion-positive patients, we also divided our patients accord-
ing to age (> 60 or ≤60 years). In the group of patients ≤60
years old, CALR mutation-positive patients had a better
overall survival than the JAK2 V617F-positive group
(P=0.04). On the other hand, in the group of patients older
than 60 years there was no difference in the overall survival
between the CALR mutation-positive group and the JAK2
V617F-positive group (P=0.19) (Figure 3). This indicates
that the prognosis of CALR/JAK2 mutated ET is different
only in younger age groups. 
We also describe, what is to the best of our knowledge,
the fourth ET patient with both a JAK2 V617F and a CALR
mutation. In this patient the JAK2 V617F mutational load
assessed by allele-specific polymerase chain reaction
analysis was around 0.2%, while the mutational load of
CALR type 2 estimated by Sanger sequencing was around
40%. Based on the differential mutational loads two sce-
narios are possible; either the JAK2 V617F is a subclonal
mutation in the major CALR mutated clone, or the two
mutations arose in two different clones with the CALR
clone being the larger, with the JAK2 V617F as a minor
clone. Given that no viable frozen material is available,
this issue unfortunately cannot be further investigated in
vitro. 
In summary, this study of 160 ET patients confirms that
CALR mutation-positive ET is phenotypically and biologi-
cally distinct from JAK2 V617F-positive ET, in terms of
clinical presentation and disease evolution. We also
observed that CALRmutant ET was associated with better
overall survival in younger ET patients. Our study also
suggests the possibility of phenotypic differences within
the CALRmutant group according to the mutation type, in
line with a few other studies.22,24 Although the analysis of
CALR mutations is rapidly being implemented in the diag-
nostic work-up of ET, the molecular subtypes of ET are, at
the time of writing, not taken into account in treatment
decisions in ET. 
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Figure 2. Overall survival, myelofibrosis-free survival, and leukemia-
free survival. Kaplan-Meier estimate of (A) overall survival of CALR-
positive, JAK2 V617F-positive, and triple-negative groups, (B) myelofi-
brosis-free survival and (C) leukemia-free survival of the CALR-posi-
tive group and JAK2 V617F-positive group.
Figure 3. Overall survival of the CALR-positive and the JAK2 V617F-
positive groups stratified into age groups. Kaplan-Meier estimate
according to age groups: greater than 60 and younger or equal to 60
years old.
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